Payment overview · 2025
General Payments
$845.63
28 reported records · 14 companies
Healthcare provider profile · identity verified
Sylvia A Gisi, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TEMECULA, CA · NPI 1720052541
Verified facts
What the public records show
CMS Open Payments records show Sylvia A Gisi, M.D. received $845.63 in general payments during 2025 across 28 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $267.93 | 31.7% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $150.67 | 17.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.92 | 9.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.14 | 7.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.57 | 7.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.35 | 4.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $37.47 | 4.4% | 2 | 2025 |
| QIAGEN, LLC | Unresolved — no canonical attribution shown | $25.03 | 3.0% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $23.41 | 2.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.17 | 2.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.33 | 2.5% | 1 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $21.31 | 2.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.57 | 2.3% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $13.76 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $845.63 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $214.89 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $189.76 | 3 | 2025 |
Source payment records
|
|||||
| OverStitch Endoscopic Suturing System Normalized: overstitch endoscopic suturing system |
Device | Boston Scientific Corporation | $150.67 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $75.92 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $64.14 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $64.14 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $62.57 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.35 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $37.47 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $37.47 | 2 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 394 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 211 | 59 |
| Metformin Hcl | Metformin Hcl | 155 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 140 | 37 |
| Losartan Potassium | Losartan Potassium | 130 | 32 |
| Lisinopril | Lisinopril | 118 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 36 |
| Meloxicam | Meloxicam | 95 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 26 |
| Simvastatin | Simvastatin | 62 | 18 |
| Synthroid | Levothyroxine Sodium | 60 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 23 |
| Januvia | Sitagliptin Phosphate | 50 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 49 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 15 |
| Gabapentin | Gabapentin | 43 | 13 |
| Azelastine Hcl | Azelastine Hcl | 42 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | suppressed |
| Ramipril | Ramipril | 42 | 12 |
| Furosemide | Furosemide | 39 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 36 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | suppressed |
| Allopurinol | Allopurinol | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | 11 |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Prednisone | Prednisone | 25 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Eliquis | Apixaban | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Omeprazole | Omeprazole | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 12 |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Vesicare | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $845.63 · 28 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, FREESTYLE LIBRE 3, GARDASIL 9, NP Thyroid 60, NURTEC ODT, OTEZLA, Omnipod, OverStitch Endoscopic Suturing System, Ozempic, REPATHA, Rybelsus, TMS NeuroHealth Centers Inc., TZIELD, VRAYLAR, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error